RS-102895 HCl (RS 102895), the hydrochloride salt of RS102895, is a novel and potent chemokine receptor CCR2 antagonist anticancer activity.

CCR8 antagonist 1 is a novel and potente human CCR8 antagonis .

INCB3344 (INCB-3344 ) is a novel, potent, selective, orally bioavailable small molecule antagonist of the CCR2 receptor with anti-inflammatory activity.

BMS-813160 (BMS813160) is a novel, potent, selective and dual antagonist of CCR2/CCR5 (CC chemokine receptor) with potential immunomodulating and antineoplastic activities.

Vicriviroc maleate (formerly known as SCH 417690; SCH-D), the maleate salt of vicriviroc, is a novel, potent, selective, orally bioavailable and CNS penetrant antagonist of CCR5 entry inhibitor of HIV-1 with a Ki of 2.5 nM, and also inhibits HIV-1 in PBMC cells, with IC90s of 3.3 nM (JrFL), 2.8 nM (ADA-M), 1.8 nM (301657), […]

Bindarit (also known as AF-2838; AF 2838) is a potent and selective inhibitor of monocyte chemotactic proteins MCP-1/CCL2, MCP-3/CCL7 and MCP-2/CCL8 with anti-inflammatory activity.

TAK-779 (TAK779) is a novel, potent and selective nonpeptide antagonist of CCR5 [C-C chemokine receptor type 5 (CCR5) receptor] and CXCR3 with potential anticancer, immunomodulatory and antiinflammatory activities.

Cenicriviroc (formerly known as TAK-652 or TBR-652) is a novel, orally bioactive, and dual antagonist of CCR2/CCR5, it also inhibits both HIV-1 and HIV-2, and has the potential for the treatment of HIV infection.

BX471 HCl (also known as BX-471; ZK-811752) is a novel, oral and non-peptide antagonist of CCR1 (CC chemokine receptor-1) with potential anti-inflammatory activity.

Aplaviroc HCl (GW873140A; ONO-4128; AK-602; GSK 873140) is the hydrochloride salt of Aplaviroc which is a SDP (spirodiketopiperazine) derivative, and a CCR5 entry inhibitor with anti-HIV activity.